These agents target upstream cytokines, thereby silencing multiple inflammatory pathways: not only eosinophils, but also affecting mast cells, basophils, IgE, and fibroblasts involved in EoE pathology [92]. The gene discussed is IGHE; the disease is eosinophilic esophagitis.